London-based Punto Health closes €645k to start a dementia care revolution
London-based Punto Health closes €645k to start a dementia care revolution unknown
Punto Health, a digital health company focused on managing Alzheimer’s and other dementias, has closed a €645k investment round. The German fund Heartfelt_, and the Spanish funds Abac Nest and Bolsa Social Fund participated in the round, along with several Business Angels, including a scout from the American fund Sequoia, Bruce Walker (scout from the British fund Ada Ventures), Gail Armstrong (through the British fund Lavender Ventures) and Branislav Trajkovski.
The Punto Health team, led by Anna Muñoz Farré and Jack Eckersley, is developing an AI-powered comprehensive platform to improve care for dementia patients and their families. The platform offers personalised content, including clinically validated resources, advice and answers tailored to each user’s needs. It proposes care plans and recommendations on healthy habits, cognitive and physical exercises, and nutrition, as well as specific resources and support for family members and carers at each stage of the disease. In addition, it has an interactive chatbot that acts as a validated personal assistant, providing a trusted companion.
“We all know someone who has been affected by dementia in one way or another, and it is only growing. By 2030, there will be over 78 million people living with dementia, so it is time to redefine cognitive care models,” said Anna, founder and CEO of Punto Health. “This investment will accelerate the development of our platform, providing patients and their families with a trusted companion every step of the way.”
In close collaboration with Ace Alzheimer Center, a European leader in the diagnosis, treatment and research of dementia, Punto Health is validating an innovative digital biomarker integrated into its platform. This biomarker makes it possible to assess cognitive status through spontaneous speech analysis, helping in the early detection and monitoring of the disease at each stage. The platform also allows health professionals to access data continuously recorded by patients, facilitating remote monitoring, early detection of abnormalities, and clinical decision-making, in order to provide comprehensive and personalised care.
Overall, Punto Health aims to empower patients to maintain their independence for as long as possible, alleviate the physical and emotional burden on family members, and equip healthcare professionals with advanced tools to optimise monitoring and treatment, thereby improving the quality of life for all those involved.
Joerg Rheinboldt, General Partner of Heartfelt_, commented: “We are thrilled to support Anna, Jack and the Punto Health team in their journey to redefine the early detection and management of dementia with their innovative biomarker approach. Their vision aligns with our commitment to investing in teams that drive meaningful change and deliver outstanding value to end customers.”
Joan Pina, Managing Partner of Abac Nest, added: “At Abac Nest Ventures, we are thrilled to invest in Punto Health, led by the highly skilled team of Anna and Jack. Punto Health impressed us with its unique technology and a business purpose that we quickly connected with: applying technology and AI to improve the quality of life for Alzheimer’s patients, while making management easier for their families and caregivers. This investment reflects our commitment to supporting AI solutions that enhance the quality of life for patients and families dealing with complex diseases.”
José Moncada, Managing Partner of Bolsa Social Fund, said: “As an impact fund, we seek to drive innovative solutions to address major social challenges in a structural way. We believe that Punto Health’s technology will improve the treatment and monitoring of Alzheimer’s and other neurodegenerative diseases, with enormous potential to significantly improve the quality of life for patients, their families, and carers.”